Last reviewed · How we verify

Wistar Rabies Virus Strain PM-1503-3M Vaccine

Fred Hutchinson Cancer Center · Phase 1 active Biologic Quality 0/100

Wistar Rabies Virus Strain PM-1503-3M Vaccine is a Biologic drug developed by Fred Hutchinson Cancer Center. It is currently in Phase 1 development. Also known as: Imovax Rabies.

At a glance

Generic nameWistar Rabies Virus Strain PM-1503-3M Vaccine
Also known asImovax Rabies
SponsorFred Hutchinson Cancer Center
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Wistar Rabies Virus Strain PM-1503-3M Vaccine

What is Wistar Rabies Virus Strain PM-1503-3M Vaccine?

Wistar Rabies Virus Strain PM-1503-3M Vaccine is a Biologic drug developed by Fred Hutchinson Cancer Center.

Who makes Wistar Rabies Virus Strain PM-1503-3M Vaccine?

Wistar Rabies Virus Strain PM-1503-3M Vaccine is developed by Fred Hutchinson Cancer Center (see full Fred Hutchinson Cancer Center pipeline at /company/fred-hutchinson-cancer-center).

Is Wistar Rabies Virus Strain PM-1503-3M Vaccine also known as anything else?

Wistar Rabies Virus Strain PM-1503-3M Vaccine is also known as Imovax Rabies.

What development phase is Wistar Rabies Virus Strain PM-1503-3M Vaccine in?

Wistar Rabies Virus Strain PM-1503-3M Vaccine is in Phase 1.

Related